康霈* (6919)

About 康霈*

Caliway Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the development of drugs for aesthetic medicine and chronic inflammation. The company develops CBL-514, an investigational drug, which is in Phase 2 clinical trial for non-surgical fat reduction and Dercum's disease, as well as for cellulite treatment. It is also developing CBA-539, which is in preclinical stage for central obesity, hyperpigmentation, and skin aging, as well as offers dietary supplements. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.

Headquarters: New Taipei City, TW · Website: https://www.caliway.com.tw

Frequently asked questions about 康霈* (6919)

What is 康霈* (6919)?

康霈* (6919) is a publicly traded company in the Healthcare sector (生技醫療業), listed on TWSE. Macroplane maps its supply-chain relationships, suppliers, buyers, financial health, and competitive positioning.